FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051157194> ?p ?o ?g. }

• W2051157194 abstract "TREATMENT of patients with systemic lupus erythematosus (SLE) has not changed substantially in the last 10 years. In general, low to moderate doses of corticosteroids and antimalarics are sufficient for mild forms of the disease, whereas high doses of corticosteroids, combined with other immunosuppressive drugs, are required for cases with affected kidneys or central nervous system (CNS). As an immunosuppressive drug, cyclophosphamide (Cy) may be applied according to different protocols, but the protocol from the National Institutes of Health (NIH), is used most frequently. 4 Side effects of therapy with Cy are numerous, some of which are very serious. The most common adverse effects include alopecia, amenorrhea, bone marrow suppression, hemorrhagic cystitis, risk of infection, and malignancy. If the dose of Cy and route of administration are carefully selected, even severe forms of SLE could be successfully treated with minimal side effects. The aim of this work was to report on our 10-year experience with high “pulse” doses of Cy in the treatment of most severe forms of SLE. For the period 1988 to 1999, a total of 178 patients (162 women and 16 men) who met the ARA criteria for diagnosis of SLE were submitted to treatment at the Clinic of Rheumatology and Clinical Immunology, MMA, Belgrade. Among these patients, 78% (139 of 178) had arthritis, 64% (114 of 178) facial butterfly erythema, 42% (75 of 178) glomerulonephritis, 19% (34 of 178) CNS manifestations according to ARA criteria, 10% (18 of 178) a severe form of skin vasculitis, and 7% (12 of 178) carditis. Of the patients with glomerulonephritis, type IIb was diagnosed in 21, type III in 21, type IV in 30, and type V in 9, according to WHO classification. In the group of patients with affected CNS, 26 had epilepsy and 8 had psychosis. High “pulse” doses of Cy were applied in 68 patients with the most severe disease: 38 patients (56%) had glomerulonephritis, about half of whom had kidney insufficiency; 24 patients (35%) had glomerulonephritis and CNS involvement; and 6 patients (9%) had CNS manifestations only (Table 1). For 22% (15 of 68) of patients, therapy with Cy came first. Another 78% (53 of 68) patients were treated previously with other therapeutic modalities, but unsuccessfully. Cyclophosphamide was administered at a dose of 10 to 15 mg/kg body weight, depending on creatinine clearance in infusion of physiologic solution, together with 40 mg methylprednisolone. Antiemetics were given before and after each infusion. In addition, extensive hydration with at least 2 L of liquid was performed. The above procedure was repeated monthly during 6 months and, thereafter, a maximum of six more times in intervals of 3 months, depending on the effect achieved after the first 6 months. Between infusions, patients were treated with corticosteroids at a dose of 15 to 30 mg/d, and also with antimalarics. Treatment efficacy was evaluated as positive if clinical, biochemical, and immunoserologic signs of disease activity were absent (complete remission), or biochemical and immunoserologic signs persisted (incomplete remission). Complete remission of disease was achieved in 75% (51 of 68) and incomplete remission in 10% (7 of 68) of patients (Table 2). A positive effect was usually obtained after a third “pulse” of Cy (range 1 to 8). These patients were treated further with low doses of corticosteroids or antimalarics, or in eight cases with azathioprine. Therapy with Cy was ineffective in 15% (10 of 68) of patients. Four patients from this group developed terminal kidney insufficiency. They did not reach remission after 6-month treatment. In such cases, cyclosporine or high doses of human intravenous immunoglobulins were applied. At present, treatment lasting 6 to 24 months" @default.
• W2051157194 created "2016-06-24" @default.
• W2051157194 creator A5002199811 @default.
• W2051157194 creator A5010033201 @default.
• W2051157194 creator A5039918530 @default.
• W2051157194 creator A5065130850 @default.
• W2051157194 creator A5081184110 @default.
• W2051157194 creator A5091122162 @default.
• W2051157194 date "2001-05-01" @default.
• W2051157194 modified "2023-09-27" @default.
• W2051157194 title "High doses of cyclophosphamide in the treatment of severe systemic lupus erythematosus" @default.
• W2051157194 cites W1971058219 @default.
• W2051157194 cites W2053582855 @default.
• W2051157194 cites W2325870812 @default.
• W2051157194 doi "https://doi.org/10.1016/s0041-1345(01)01998-4" @default.
• W2051157194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11377536" @default.
• W2051157194 hasPublicationYear "2001" @default.
• W2051157194 type Work @default.
• W2051157194 sameAs 2051157194 @default.
• W2051157194 citedByCount "1" @default.
• W2051157194 crossrefType "journal-article" @default.
• W2051157194 hasAuthorship W2051157194A5002199811 @default.
• W2051157194 hasAuthorship W2051157194A5010033201 @default.
• W2051157194 hasAuthorship W2051157194A5039918530 @default.
• W2051157194 hasAuthorship W2051157194A5065130850 @default.
• W2051157194 hasAuthorship W2051157194A5081184110 @default.
• W2051157194 hasAuthorship W2051157194A5091122162 @default.
• W2051157194 hasConcept C126322002 @default.
• W2051157194 hasConcept C141071460 @default.
• W2051157194 hasConcept C159654299 @default.
• W2051157194 hasConcept C16005928 @default.
• W2051157194 hasConcept C197934379 @default.
• W2051157194 hasConcept C203014093 @default.
• W2051157194 hasConcept C2775915377 @default.
• W2051157194 hasConcept C2776015282 @default.
• W2051157194 hasConcept C2776581026 @default.
• W2051157194 hasConcept C2776694085 @default.
• W2051157194 hasConcept C2776755627 @default.
• W2051157194 hasConcept C2779134260 @default.
• W2051157194 hasConcept C71924100 @default.
• W2051157194 hasConcept C90924648 @default.
• W2051157194 hasConceptScore W2051157194C126322002 @default.
• W2051157194 hasConceptScore W2051157194C141071460 @default.
• W2051157194 hasConceptScore W2051157194C159654299 @default.
• W2051157194 hasConceptScore W2051157194C16005928 @default.
• W2051157194 hasConceptScore W2051157194C197934379 @default.
• W2051157194 hasConceptScore W2051157194C203014093 @default.
• W2051157194 hasConceptScore W2051157194C2775915377 @default.
• W2051157194 hasConceptScore W2051157194C2776015282 @default.
• W2051157194 hasConceptScore W2051157194C2776581026 @default.
• W2051157194 hasConceptScore W2051157194C2776694085 @default.
• W2051157194 hasConceptScore W2051157194C2776755627 @default.
• W2051157194 hasConceptScore W2051157194C2779134260 @default.
• W2051157194 hasConceptScore W2051157194C71924100 @default.
• W2051157194 hasConceptScore W2051157194C90924648 @default.
• W2051157194 hasLocation W20511571941 @default.
• W2051157194 hasLocation W20511571942 @default.
• W2051157194 hasOpenAccess W2051157194 @default.
• W2051157194 hasPrimaryLocation W20511571941 @default.
• W2051157194 hasRelatedWork W180182630 @default.
• W2051157194 hasRelatedWork W1963970819 @default.
• W2051157194 hasRelatedWork W1990850302 @default.
• W2051157194 hasRelatedWork W2017709470 @default.
• W2051157194 hasRelatedWork W2031799718 @default.
• W2051157194 hasRelatedWork W2085178500 @default.
• W2051157194 hasRelatedWork W2119406770 @default.
• W2051157194 hasRelatedWork W2126911786 @default.
• W2051157194 hasRelatedWork W2128459490 @default.
• W2051157194 hasRelatedWork W2129277631 @default.
• W2051157194 hasRelatedWork W2130929166 @default.
• W2051157194 hasRelatedWork W2134098269 @default.
• W2051157194 hasRelatedWork W2137703086 @default.
• W2051157194 hasRelatedWork W2148306888 @default.
• W2051157194 hasRelatedWork W2162112605 @default.
• W2051157194 hasRelatedWork W2164608576 @default.
• W2051157194 hasRelatedWork W2165467213 @default.
• W2051157194 hasRelatedWork W2298810042 @default.
• W2051157194 hasRelatedWork W231114871 @default.
• W2051157194 hasRelatedWork W42940117 @default.
• W2051157194 isParatext "false" @default.
• W2051157194 isRetracted "false" @default.
• W2051157194 magId "2051157194" @default.
• W2051157194 workType "article" @default.